Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Change in Receivables (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Change in Receivables for 11 consecutive years, with $1000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Receivables changed N/A year-over-year to $1000.0, compared with a TTM value of $502000.0 through Sep 2025, up 656.52%, and an annual FY2024 reading of $900000.0, changed N/A over the prior year.
  • Change in Receivables was $1000.0 for Q3 2025 at Lisata Therapeutics, up from -$249000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $900000.0 in Q4 2024 and bottomed at -$249000.0 in Q2 2025.